Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy — Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right — — Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with hyperammonemia (excess ammonia in the blood) that occurs as complications of liver disease, such as cirrhosis — — Roughly 200,000 U.S. hospitalizations result from acute HE each year; approximately 1.5 to 2 million patients are at risk of recurrent HE — — Average of $30,000-$60,000 per hospital stay; total acute and recurrent HE market potential opportunity of $5.0-$7.0 billion — — If approved, OCR-002 is expected to become the first intravenous pharmacologic option indicated for treatment of acute HE in the U.S.; FDA Orphan Drug designation and Fast Track status granted; EMA Orphan Drug designation — — Acquisition further expands Mallinckrodt’s focus on treatments for severe and critical diseases in hepatic and renal conditions; diversifies portfolio pipeline with differentiated, highly durable product which aligns well with company’s terlipressin development asset — — Assuming expected 2017 close, company expects dilution from acquisition to adjusted diluted earnings per share of approximately $0.25 to $0.35 annually beginning in 2018 — PR Newswire STAINES-UPON-THAMES, United Kingdom, and REDWOOD CITY, Calif., Nov. 2, 2017 STAINES-UPON-THAMES, United Kingdom , and REDWOOD CITY, Calif. […]